To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
How TPG’s decade-long thematic focus lent to the creation Ellodi, a new specialty pharma business
Ellodi's clinical assets were spun out of TPG's Adare, which grew EBITDA at a CAGR north of 25 percent under the PE firm's hold, a source told PE Hub.
